Assembly Biosciences, Inc. (ASMB), a biotechnology company focused on developing therapies for serious viral diseases, on Thursday announced positive interim results from its ongoing Phase 1b clinical trial evaluating ABI-4334, a next-generation capsid assembly modulator for chronic hepatitis B virus infection.
In the first cohort of the phase Ib study, participants who received a 150 mg dose of ABI-4334 once daily for 28 days showed strong antiviral activity, with a mean reduction of 2.9 log10 IU/mL in plasma HBV DNA.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com